A Phase 1 First-in-Human Study Evaluating AMG 900 in Advanced Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

95

Participants

Timeline

Start Date

August 10, 2009

Primary Completion Date

December 31, 2014

Study Completion Date

April 3, 2019

Conditions
Advanced MalignancyAdvanced Solid TumorsCancerSolid TumorsTumors
Interventions
DRUG

Arm 1- Dose Escalation

AMG 900 is a small molecule inhibitor of aurora kinases A, B and C. AMG 900 will be administered daily for 4 days every 2 weeks (i.e., 4 consecutive days of dosing followed by 10 consecutive days off treatment).

DRUG

Arm 1- Dose Expansion

AMG 900 is a small molecule inhibitor of aurora kinases A, B and C. AMG 900 will be administered daily for 4 days every 2 weeks (i.e., 4 consecutive days of dosing followed by 10 consecutive days off treatment).

Trial Locations (8)

3050

Research Site, Parkville

3165

Research Site, Bentleigh East

5037

Research Site, Kurralta Park

21231

Research Site, Baltimore

85724

Research Site, Tucson

87131

Research Site, Albuquerque

89148

Research Site, Las Vegas

90095

Research Site, Los Angeles

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Amgen

INDUSTRY